Clinical trials: Neoplasm, Brain
Pituitary Neuroendocrine Tumors
A Comparative Study of Patients Undergoing Surgery for Pituitary Neuroendocrine Tumors Detected by Different Ways
This multicenter cohort study is based on the National Brain Tumor Registry of China (NBTRC). It will compare patients who underwent surgery for Pituitary Neuroendocrine Tumors (PitNETs) detected through health screening versus…
- Trial name
- NCT07835412
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Beijing Tiantan Hospital
Solid Tumour Neoplastic Meningitis, Brain Metastases
Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.
The purpose of this study is to demonstrate the safety of giving Whole Brain Radiotherapy (WBRT) together with intrathecal liposomal cytarabine (DepoCyte®) for patients with leptomeningeal metastases.
- Trial name
- NCT00854867
- Testing
- Whole Brain Radio Therapy (WBRT) with sequential Depocyte, Whole brain radiotherapy (WBRT) with concomitant Depocyte
- Where
- 7 sites in Austria, Germany
- Volunteers
- 18 people
- Sponsor
- Mundipharma Research Limited
Organic, Including Symptomatic, Mental Disorders, Substance Use
Exploring the Comorbidity Between Mental Disorders and General Medical Conditions
Mental disorders have been shown to be associated with a number of general medical conditions (also referred to as somatic or physical conditions).
- Conditions
- Organic, Including Symptomatic, Mental Disorders, Substance Use, Schizophrenia, Mood [Affective] Disorders
- Trial name
- COMO-GMC (NCT03847753)
- Testing
- Organic Disorders, Substance Use Disorders, Schizophrenia Disorders
- Volunteers
- 5,940,299 people
- Sponsor
- University of Aarhus
Cancer
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant.
- Trial name
- NCT00110045
- Testing
- caspofungin acetate
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
High-Grade Glioma (WHO III-IV)
FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma
This clinical trial aims to determine if FG001 can assist surgeons in identifying the difference between tumor and healthy tissue during surgery in participants with newly diagnosed high-grade glioma.
- Trial name
- NCT07609472
- Testing
- FG001
- Where
- 5 sites in United States
- Volunteers
- 76 people
- Sponsor
- FluoGuide A/S
Metastatic Malignant Neoplasm in the Brain
Frameless Fractionated Stereotactic Radiation in Treating Patients With Brain Metastases
This phase II trial studies the safety and efficacy of frameless fractionated stereotactic radiation therapy for brain metastases.
- Trial name
- NCT02798029
- Testing
- Frameless Fractionated Stereotactic Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Tumor, Vascular Lesion
Factor XIII and Pulmonary Embolism in Neurosurgical Patients
Two studies (Gerlach et al. 2000; Gerlach et al. 2002) described the impact of factor XIII on the risk of prospective hemorrhage for patients undergoing craniotomy.
- Conditions
- Brain Tumor, Vascular Lesion, Factor XIII Deficiency, Pulmonary Embolism
- Trial name
- NCT01106937
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Ischemic Stroke, Mild
ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)
The purpose of this study is to investigate the safety and efficacy of rhPro-UK (35mg) versus standard medical treatment in acute mild ischemic stroke within 4.5 hours of symptom onset.
- Conditions
- Ischemic Stroke, Mild, Thrombosis
- Trial name
- PUMICE (NCT05507645)
- Testing
- Recombinant Human Prourokinase for Injection (rhPro-UK), standard medical treatment
- Where
- 89 sites in China
- Volunteers
- 1,446 people
- Sponsor
- Beijing Tiantan Hospital
Breast Cancer
SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases
The aim of this project is to evaluate whether the sequence of Trastuzumab，pyrotinib and Nab-Paclitaxel in first line followed by SHR-A1811 in second line is superior to the sequence of SHR-A1811 in first line followed by…
- Trial name
- NCT06975475
- Testing
- SHR-A1811,tratuzumab,pyrotinib,Nab-Paclitaxel
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Metastatic Cancer, Radiation Toxicity
Melatonin and Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as melatonin may make tumor cells more sensitive to radiation therapy and may protect normal cells from the side effects of radiation therapy.
- Conditions
- Metastatic Cancer, Radiation Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00031967
- Testing
- therapeutic melatonin, radiation therapy
- Where
- 234 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
This phase II trial is studying how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with recurrent or progressive glioblastoma.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT01122901
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, pharmacological study
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Brain Tumors
Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
RATIONALE: Current therapies for adults with primary malignant brain tumors that have not responded to standard therapy provide very limited benefit to the patient.
- Trial name
- NCT00003475
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Burzynski Research Institute
Brain Neoplasms, Neuroblastoma
Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy
This is a pharmacokinetic trial. Patients receive phenylbutyrate through a central venous catheter for each 28 day cycle. The first several days of drug administration should be inpatient.
- Trial name
- NCT00001565
- Testing
- phenylbutyrate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia
- Trial name
- NCT00074165
- Testing
- Rituxan, Cyclophosphamide, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- OHSU Knight Cancer Institute
Brain and Central Nervous System Tumors, Neuroblastoma
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
RATIONALE: Monoclonal antibodies can locate tumor cells and deliver tumor-killing substances, such as radioactive iodine, to them without harming normal cells.
- Trial name
- NCT00003484
- Testing
- carmustine, irinotecan hydrochloride, surgical procedure
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Darell D. Bigner, MD, PhD
Cognitive/Functional Effects, Metastatic Cancer
Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x rays to kill tumor cells.
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Radiation Toxicity
- Trial name
- NCT01372774
- Testing
- stereotactic radiosurgery, whole-brain radiation therapy
- Where
- 37 sites in United States
- Volunteers
- 194 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Brain and Central Nervous System Tumors
Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Trial name
- NCT00003574
- Testing
- surgical procedure, brachytherapy, intraoperative radiation therapy
- Where
- 9 sites in United States
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
Central Nervous System Tumour
Neurocognitive Integrity After Proton Therapy for Brain Tumor
Radiation therapy remains a cornerstone in the management of both benign and malignant intracranial tumors, either as monotherapy or combined with surgery and/or chemotherapy.
- Trial name
- PROTON MIND (NCT07836478)
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- European Institute of Oncology
Major Gynecological Cancer Surgery, Low Flow Anesthesia
The Relationship Between Body Mass Index and Patient Outcomes in Low Flow Anaesthesia
This study was designed as a prospective observational study.
- Trial name
- NCT06636448
- Testing
- the effect of body mass index during low-flow anesthesia
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Adult Ependymoblastoma, Adult Giant Cell Glioblastoma
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
This pilot phase I/II trial studies the side effects and best dose of plerixafor after radiation therapy and temozolomide and to see how well it works in treating patients with newly diagnosed high grade glioma.
- Conditions
- Adult Ependymoblastoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT01977677
- Testing
- radiation therapy, temozolomide, plerixafor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Lawrence Recht
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.